Compare BLFS & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLFS | EVO |
|---|---|---|
| Founded | 1987 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 1989 | 2021 |
| Metric | BLFS | EVO |
|---|---|---|
| Price | $24.61 | $2.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $31.50 | $7.00 |
| AVG Volume (30 Days) | ★ 352.6K | 93.1K |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $100,144,000.00 | ★ $887,396,457.00 |
| Revenue This Year | $20.67 | N/A |
| Revenue Next Year | $14.13 | $8.80 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 87.53 | N/A |
| 52 Week Low | $19.10 | $2.82 |
| 52 Week High | $29.62 | $5.10 |
| Indicator | BLFS | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 40.40 | 38.23 |
| Support Level | $24.68 | $2.86 |
| Resistance Level | $25.96 | $3.24 |
| Average True Range (ATR) | 1.05 | 0.10 |
| MACD | -0.08 | 0.01 |
| Stochastic Oscillator | 20.73 | 22.45 |
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.